purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation axsm earnings call period ending march image source motley fool axsome therapeutic axsm q earnings callmay etcontents prepared remark question answer call participant prepared remark operatorgood morning welcome axsome therapeutic conference call currently participant listenonly mode later questionandanswer session instruction follow time operator instruction reminder today conference call recorded would like turn conference host darren opland director corporate communication axsome therapeutic please go aheaddarren opland director corporate communication good morning thank joining u today conference call morning issued earnings press release providing corporate update detail company financial result first quarter release crossed wire short time ago available website axsomecom today call making certain forwardlooking statement statement may include statement regarding among thing efficacy safety intended utilization investigational agent clinical nonclinical plan plan present report additional data anticipated conduct source future clinical trial regulatory plan future research development plan commercial plan regarding sunosi auvelity pipeline product revenue projection possible intended use cash investment forwardlooking statement based current information assumption expectation subject change involve risk uncertainty may cause actual result differ materially contained forwardlooking statement risk described periodic filing made security exchange commission including quarterly annual report cautioned place undue reliance forwardlooking statement made today date company disclaims obligation update statementsjoining call today dr herriot tabuteau chief executive officer nick pizzie chief financial officer mark jacobson chief operating officer ari maizel executive vice president head commercial herriot provide overview company progress made first quarter well key upcoming milestone following herriot nick review financial result ari provide commercial update open line question question taken order received turn call herriot herriot tabuteau chief executive officer thank darren good morning everyone thank joining axsome therapeutic firstquarter financial result business update conference call first quarter marked strong financial performance onmarket product delivering important differentiated treatment option patient living depression narcolepsy obstructive sleep apnea total net product revenue quarter million representing yearoveryear growth approximately share additional detail financial commercial performance later call also significantly advanced innovative neuroscience pipeline quarter including announcing positive topline result ax narcolepsy advancing ax ax toward nda submission initiating pivotal trial new indication solriamfetol advancing expanding alzheimers disease agitation program ax expect continue commercial pipeline momentum balance provide brief update industryleading neuroscience pipeline expected milestone starting two ndastage product ax acute treatment migraine track nda resubmission quarter additionally conducting emerge study multicenter phase singlegroup trial evaluating efficacy safety ax adult prior inadequate response oral cgrp inhibitor anticipate topline result trial second half ax developing treatment fibromyalgia presubmission activity nda product nearing completion continue target submission later quarter march announced phase symphony trial ax narcolepsy achieved primary endpoint significantly reduced frequency cataplexy attack compared placebo ax also reduced excessive daytime sleepiness severity improved cognition reduced overall narcolepsy severity openlabel safety extension trial ax ongoing result expected fourth quarter excited potential ax provide differentiated treatment option patient hcps debilitating condition moving ax continue anticipate completion phase advance trial treatment alzheimers disease agitation second half today announced launched accord study doubleblind placebocontrolled randomized control trial evaluate efficacy safety ax treatment alzheimers disease agitation study similar design completed positive accord trial accord clinical development program include four controlled efficacy trial importantly accord increase robustness clinical program allows disease agitation without impacting overall development timeline enrollment accord far along expect enrollment completion around midyear respect solriamfetol dopamine norepinephrine reuptake inhibitor taar agonist addition continued commercial performance launched phase paradigm trial major depressive disorder phase engage trial binge eating disorder first quarter result trial expected track initiate phase clinical program shift work disorder quarter solriamfetol also evaluated focus phase trial adhd continue anticipate topline result second half year overall innovative neuroscience portfolio encompasses five latestage patentprotected product candidate targeting serious psychiatric neurological condition substantial market opportunity product candidate potential transform treatment landscape serious difficulttotreat cns disorder affect million people yous turn call nick provide detail financial performance nicknick pizzie chief financial officer thank herriot good morning today discus firstquarter result provide financial guidance total product revenue million first quarter consisted net product sale million royalty revenue total product revenue comparable period million consisted net product sale million royalty revenue million onetime license revenue received outlicensing sunosi certain exyous territory auvelity net product sale million first quarter representing yearoveryear growth auvelity net product sale comparable period million sunosi net product revenue million first quarter consisted million product sale royalty revenue associated sunosi sale licensed territory sunosi net product revenue comparable period million consisting million product sale royalty revenue total cost revenue million first quarter total cost revenue comparable period million included million sunosi licensing transaction feesharing expense research development expense million first quarter compared million comparable period increase primarily related initiation solriamfetol paradigm trial major depressive disorder solriamfetol engage trial binge eating disorder advancement solriamfetol focus trial adhd ongoing trial ax ax manufacturing cost associated anticipated ndas ax ax postmarketing commitment auvelity sunosi higher personnel cost including noncash stockbased compensation selling general administrative expense million first quarter compared million comparable period increase primarily related commercialization activity auvelity sunosi including sale force marketing expense higher personnel cost related organizational growth including noncash stockbased compensation net loss first quarter million per share compared net loss million per share comparable period net loss first quarter includes million noncash charge majority comprised noncash stockbased compensation expense comparable period included approximately million net gain sunosi outlicensing q typically negative seasonality effect gtn saw auvelity sunosi versus prior quarter auvelity gtn discount q low mids sunosi gtn discount mids ended first quarter million cash cash equivalent compared million yearend believe current cash balance sufficient fund anticipated operation cash flow positivity based current operating plan like turn call ari provide commercial updateari maizel executive vice president head commercial thank nick axsome delivered solid brand performance first quarter auvelity demand trend q outpaced growth rate market branded competitor approximately prescription representing quarteroverquarter growth growth compared first quarter nearly new patient started auvelity quarter bringing total number unique patient treated auvelity since launch sale team continues activate new prescribers consistent rate firsttime auvelity prescribers q illustrating strong underlying demand product expanded use among depression treater psychiatry primary care office especially proud performance light seasonal dynamic compounded industrywide change healthcare cyberattack payer coverage stable q auvelity remains accessible patient representing approximately covered life noted press release morning contracted large group purchasing organization potential formulary coverage auvelity laying groundwork future increase covered life pharmacy benefit manager health plan gpo able make coverage decision auvelity based contracted term agreement axsome contracted two three largest gpo potential coverage auvelity pleased strong commercial foundation created support auvelity performance including expanded psychiatry sale team recently enhanced sale marketing campaign expansion digital capability maximize reach targeted hcps note observed inflection weekly new patient start nbrx march positive signal impact optimized commercial footprint continued adoption auvelity goto treatment option adult major depressive disorder transitioning sunosi total prescription representing decline versus q growth versus q demand first quarter impacted typical seasonality ed market evidenced decline observed wakepromoting agent market quarter approximately new patient started sunosi treatment quarter bringing total number unique patient treated sunosi approximately since launch new writer activated q resulting total cumulative prescriber base since launch payer coverage sunosi q remained life covered across channel closing q positive start auvelity sunosi leading indicator trend new patient start newly activated prescribers reinforcing confidence axsome deliver strong commercial performance second year commercial company continue receive compelling feedback healthcare professional patient positive impact product realworld setting proud axsomes growing reputation leader cns space delivers differentiated impactful product serious psychiatric neurological condition turn call back darren qadarren opland director corporate communication thank ari operator may please first question question answer operatorthank conducting questionandanswer session operator instruction first question come charles duncan cantor fitzgerald please proceed questioncharles duncan cantor fitzgerald analyst hey good morning herriot team congrats great quarter appreciate taking question commercial question one pipeline regarding commercial question sure heard ari speaking fast give u sense newtobrand versus refill rate auvelity thanksari maizel executive vice president head commercial yeah thanks charles new brand moment account roughly weekly prescription know healthy number moment expect new brand continue grow trx obviously outpace based existing patient base refill rate point feel comfortable seeing good adherence persistency generally hopefully answer question let know specific followupscharles duncan cantor fitzgerald analyst little color persistency know probably early feel far auvelityari maizel executive vice president head commercial yeah feel really good fact recently engaged group kols receive feedback anecdotal know specific claim data prove seeing adherence know roughly twice seen historically ssri bodes well brand showing know impact clinical profile meaningful patient sticking longer antidepressant pastcharles duncan cantor fitzgerald analyst ok term development perhaps herriot provide u information percent responder rate anticipate first part accord study sense feel brexpiprazole changed unmet need would anticipate ax become front line would guess would sequence brexpiprazole use patient thanksherriot tabuteau chief executive officer thanks question regard responder rate accord want misspeak term exact responder rate exactly modeled included inclusion criterion accord study similarly designed reminder accord trial able effectively detect signal term brexpiprazole unmet need view brexpiprazole changed need safe effective know longterm treatment alzheimers disease agitation reminder patient treated offlabel necessarily atypical antipsychotic brexpiprazole fall class view view opportunity ax changing materially based upon approval term frontline usage assuming continue generate data replicates saw advance also accord would fully expect ax could frontline treatment would frontline treatment alzheimers disease agitationcharles duncan cantor fitzgerald analyst make sense thanks taking questionsoperatorour next question come leonid timashev rbc capital market please proceed questionleonid timashev rbc capital market analyst hey guy congrats quarter good quarter thanks taking question guy talk price volume impact would expect latest gpo add expect acceleration script impact gross net near term would incremental gradual change maybe related two three major gpo hand talk maybe progress third made thanksari maizel executive vice president head commercial yeah thanks leonid ari regarding price volume tradeoff little premature talk impact gross net particular agreement obviously part effort right ensure effectively pulling contract term pbms underneath gpo umbrella expect volume growth able expand coverage provide update impact gross net know appropriate regarding question around third gpo would say know fruitful discussion major payer pbms including gpo know complicated negotiation obviously important u expand coverage also mindful profitability long term growing portfolio need plan specific detail negotiation feel good nature dialogue look forward future updatesleonid timashev rbc capital market analyst thanksoperatorour next question come ash verma ubs please proceed questionash verma ubs analyst hey thanks thanks taking question congrats progress want last comment gpo maybe elaborate like percentage commercial life covered gpo coverage prior believe second regarding new study ad agitation remind u like like something need regulatory package think advance study would sufficient like study versus already another study going successful randomized withdrawal study earlier wanted get thought thanksherriot tabuteau chief executive officer sure thanks question two question take last one turn ari answer first question regard accord trial need regulatory submission opportunity u increase robustness program also affecting timing nda submission made sense want robust package strongest package going nda review important indication always helpful generate additional data may also know may also term regulatory submission also term future publication useful commercial perspective know think right thing efficient allows u leverage large number patient experiencing stable response current openlabel safety efficacy trialari maizel executive vice president head commercial yeah ash ari question around percent life new gpo obviously know gpo represent pool pbms pbms different number life covered ability make coverage decision give specific number incremental percentage life covered meaningfully publicly stated today part focus know moving forward ensure majority pbms underneath gpo accessing rate agreed meaningful percentage increase successful pbms underneath umbrellaoperatorour next question come ram selvaraju hc wainwright please proceed questionram selvaraju hc wainwright company analyst thanks much taking question quickly commercial front wondering specific factor expect impact discussion third three largest gpo currently looking secure contracting auvelity factor might development side wondering herriot maybe could comment profile ax relative existing approved marketed agent whether believe impact cataplexy likely significant selling point anticipate impact sleepiness going sufficient ax positioned commercially competitive way indication thanksari maizel executive vice president head commercial sure start first question factor impact negotiation generally speaking demand growth driving marketplace fact recent access discussion really focus quickly brand growing know best way secure access show volume growth absence formal coverage think important note know rule negotiate coverage major plan pbms one area focus optimize patient saving reimbursement support service support continued demand growth within existing access paradigm ability drive growth primary factor driving interest gpo major plan pbms really know proud growth seen start year know mentioned opening comment seen increase weekly new patient start march compared december existing access strengthens ability negotiate ultimately meaningful discussion insurance companiesram selvaraju hc wainwright company analyst started dtc promotion auvelity know extentari maizel executive vice president head commercial well dtc largely digital space moment currently tv video ad running something consideration moment know share update appropriateram selvaraju hc wainwright company analyst great thanksherriot tabuteau chief executive officer ram regard question ax profile saw trial replication saw concert study pretty important significant impact cataplexy large percent reduction cataplexy looked remission cataplexy total elimination result stark third patient reduction cataplexy attack versus le patient placebo group also see effect excessive daytime sleepiness severity well cognition like profile profile relates agent currently market incredibly favorable know agent market patient fact minority patient actually tolerate significant unmet need conduct also large patient survey ntrk patient conjunction narcolepsy network showed even current treatment patient continue experience cataplexy relates question around whether around ed data generated would enough clinician patient think adopting product saw study clear impact excessive daytime sleepiness also saw clear impact overall narcolepsy severity ax reduced excessive daytime sleepiness severity also improved overall narcolepsy severity well quality life way think product made available clinician patient profile apparent patient clinician treated based patientreported outcome well clinician global impression outcome really like profile think important treatment patientsram selvaraju hc wainwright company analyst thank muchoperatorour next question come marc goodman leerink please proceed questionmarc goodman leerink partner analyst good morning nick talk inventory auvelity quarter anything unusual may helped sale second talk gross net thinking rest year contract put place know thinking next couple year herriot talk ad agitation one second obviously know last quarter delay exactly sure second half completion advance maybe give u little color like back track going something going happen early second half year late second half year confirm new study talking patient already gone openlabel really competing right thanksnick pizzie chief financial officer hey marc nick inventory inventory remains channel two week nothing changed specifically around inventory auvelity sunosi remains continuing two week auvelity gtn discount q low mids sunosis gtn discount mids quarter know q typically seasonality negative seasonality effect gtn saw auvelity sunosi versus prior quarter auvelity gtn fluctuate q ended quarter march mids right reason expect vary significantly level moving forwardherriot tabuteau chief executive officer ok great marc relates question around alzheimers disease agitation starting advance guidance second half year comfortable remain comfortable guidance based enrollment trend seeing positive regard study proceeding relates accord competing advance correct large number patient openlabel portion experiencing stable response allows u efficiently enroll accord expect enrollment accord complete complete midyear know reason confidence around study far along term enrollmentmarc goodman leerink partner analyst understand advance enrollment really picked past three month confidentherriot tabuteau chief executive officer confident based enrollment enrollment advance also far along continues enroll predictable pacemarc goodman leerink partner analyst ok thanksoperatorour next question come david amsellem piper sandler please proceed questiondavid amsellem piper sandler analyst couple question pipeline first reboxetine narcolepsy remind u path forward word expecting file completed extension gating item nda filing talk timeline filing reboxetine narcolepsy cataplexy solriamfetol talk pediatric adhd study plan believe gating item filing adhd would helpful talk lastly esreboxetine fibromyalgia big commercial priority extent going need expand commercial organization support product commercially thank youherriot tabuteau chief executive officer thank question take first two ax solriamfetol let ari comment esreboxetine term timing nda filing ax gating factor completion openlabel safety extension trial expect complete second half year take u time know put together nda filing gating factor study completed able file nda relates solriamfetol pediatric adhd study plan correct trial need part initial nda package working imagine term speaking fda get place yet provided precise guidance study targeting start year regard esreboxetineari maizel executive vice president head commercial yeah thanks question think ax fibromyalgia view meaningful commercial opportunity three approved agent lot room improvement term overall clinical profile patient feel optimistic profile ax offer patient relates know impact sort commercial footprint know part analyzing year effectively size structure sale force accommodate growing portfolio product although fibromyalgia know psychiatric product lot overlapping comorbidity major depressive disorder influence thinking little early say know many additional rep would want build plan would structure think way promote ax efficiently also putting plenty attention approved product marketdavid amsellem piper sandler analyst helpful thank youoperatorour next question come yatin suneja guggenheim partner please proceed questionyatin suneja guggenheim partner analyst hey guy thank taking question two quick one one clarification one regard accord study new study fourth study within ad umbrella requirement fda two randomized withdrawal study nda package contingent upon completion study outcome study one regard auvelity mean nice quarter congrats thought thinking providing guidance product maybe quarterly yearly basis thank younick pizzie chief financial officer yeah yeah sure hey yatin thanks question nick early axsome auvelitys life cycle provide sale guidance given fluid nature market dynamic unpredictability external factor could different impact shared believe peak sale auvelity mdd alone billion billion range sunosi milion million current indicationsherriot tabuteau chief executive officer yatin regard accord fda requirement however increase robustness package pivotal trial like like four different study basically think advance advance parallel group study accord accord two randomized withdrawal study nice source evidence generation four study regard nda filing contingent upon completion study since required really contingent however think based upon enrollment study expect study fully enrolled midyear also timing relapse accord trial positive potential study read around yearend formal guidance formal guidance would based upon number relapse timing relapse give sense one might think really happy way able efficiently increase robustness program important productoperatorour next question come jason gerberry bank america please proceed questionjason gerberry bank america merrill lynch analyst hey guy thanks taking question accord sound like motivation study know kind like think marketing study along line opportunity pull accord know data better chance getting label given accord really small trial guy mention cyberattack q know peer kind indicated really material impact number quantify extent cyberattack affect auvelity revenue q thanksherriot tabuteau chief executive officer sure regard accord clear used marketing obviously registration trial know like provide objective source evidence relates able pull accord two study similarly designed could definitely combined typically something done nda packagesari maizel executive vice president head commercial yeah regarding change healthcare cyberattack impact auvelity really focused two week end february beginning march basically saw know roughly impact weekly prescription couple week time put number technology optimization patient saving optimization saw quick bounceback early midmarch demand trend stable since stable growing since largely behind u point expect continued disruption know brand impactful related time market know whether patient saving card tied change healthcare switch thing nature impacted u transient nature feel really good solution put place seen really nice growth sincejason gerberry bank america merrill lynch analyst thank youoperatorour next question come joon lee truist security please proceed questionjoon lee truist security analyst yeah thanks much thanks taking question regarding accord rationale behind designing randomized controlled trial opposed standard inaudible trial appeared better success endpoint accord identical used accord thank muchherriot tabuteau chief executive officer thanks joon somewhat muffled try answer question way interpreted necessarily said think question around accord rationale design versus design rationale wanted take advantage already fact study treating patient openlabel fashion therefore would allow assessment stable response made lot sense since since since openlabel safety extension trial essentially way randomized control study begin rationale term endpoint compared accord endpoint identical way u able take learning accord apply accord generate additional datajoon lee truist security analyst thank youoperatorour next question come joel beatty baird please proceed questionjoel beatty robert w baird company analyst right thanks taking question first one auvelity could provide breakdown usage earlierline laterline therapy second large purchasing contract could use earlierline therapy impacted allari maizel executive vice president head commercial yeah hey ari thanks question seen really nice increase since last quarter line therapy increase saw know roughly increase first second line use point around auvelity prescription first second line know healthy trend expect continue question around gpo contract impact line therapy generally speaking negotiate plan pbms negotiating first secondline access patient would expect successful pulling contract term would increase know earlier usage auvelity patientsjoel beatty robert w baird company analyst thanks last question provide context spending trajectory looking going forwardari maizel executive vice president head commercial sorry hard hear mind repeating questionjoel beatty robert w baird company analyst sure spending trajectory look going forward spending overall rd sga onnick pizzie chief financial officer got thanks thanks question rd expense quarter million ticked slightly previous quarter expect rd spend continue increase gradually two solriamfetol phase trial commence quarter third starting q shift work partially offset completion symphony trial ax reminder q plan submit nda fibromyalgia onetime charge nda filing fee sga total expense quarter million mentioned opening remark higher previous quarter anticipated really related sale force expansion would anticipate sga expense range future quartersjoel beatty robert w baird company analyst thank youoperatorour next question come david hoang citi please proceed questiondavid hoang citi analyst hi good morning thanks taking question congrats quarter want ask impact gpo negotiation term timing know increase number commercial covered life guess could cadence covered life pick look like look toward next quarter know potentially seeing meaningful stepup number covered life thanksari maizel executive vice president head commercial thanks question david expect coverage increase difficult predict exact timing way think gpo effectively gatekeeper pbms first step toward securing access agreeing contract term include rebate utilization management parameter agreement announced today enables pbms umbrella access contracted rate member provide specific percentage increase covered life today say depending many pbms underneath umbrella access rate meaningful increase timing difficult provide question next quarter obviously intent try improve quickly possible provide update appropriate timeoperatorour next question come graig suvannavejh mizuho please proceed questionavantika joshi mizuho security analyst hi avantika greg question ax thought branding ax ad agitation would keep auvelity brand thanks congrats quarterherriot tabuteau chief executive officer thanks question whenever new indication especially one different case ax ad agitation versus major depressive disorder always consideration one requires lot good thought something answered fly would require u really think quantitative work stay tuned something would obviously communicate announce ahead time something working ari anything would add thatari maizel executive vice president head commercial think spot think reality advantage disadvantage either maintaining name alternative brand name going work right anticipation filing roadavantika joshi mizuho security analyst great thank youoperatorour next question come vikram purohit morgan stanley please proceed questionvikram purohit morgan stanley analyst hi good morning thanks taking question two one auvelity one pipeline auvelity could talk bit expect sale force expansion completed recently help kind inflect script inflect sale throughout rest year whether would expect kind visible kind acute lift either metric next couple quarter secondly solriamfetol adhd confirm phase readout expected second half year going study based submit potentially filing indication also could kind frame u reporting would think constitutes successful readout would helpful thank youari maizel executive vice president head commercial sure yeah start auvelity question sale force expansion seeing impact certainly activity level effort customer seeing know roughly increase weekly call customer engaging broader group provider includes primary care audience seeing meaningful increase new prescription total prescription primary care sort commensurate additional focus able provide expanded sale team would say early phase seeing impact demand perspective referenced opening comment seen increase weekly new patient start typically first indicator demand growth reaching inflection still early day many way expect net growth continue time feel really optimistic impact sale force expansion thus far expect continue build course yearherriot tabuteau chief executive officer great regard solriamfetol current adhd study phase trial registration trial study would enable nda filing along study pediatric patient need include data efficacy data pediatric patient required kind adhd nda filing looking forward result focus trial second half year track relates looking well think first thing looking demonstrate efficacy first large multicenter randomized parallelgroup study looking result inform profile product one prior study solriamfetol adhd sponsored investigatorinitiated trial singlecenter study focus study first multicenter trialoperatorour next question come matt kaplan ladenburg thalmann please proceed questionmatt kaplan ladenburg thalmann company analyst hey good morning guy congrats quarterly result quick followup adhd program solriamfetol guess wait readout adult study prior starting pediatric study adhdherriot tabuteau chief executive officer would know goal start pediatric study soon practicablematt kaplan ladenburg thalmann company analyst great thanksoperatorwe time question two analyst next question come myles minter william blairmyles minter william blair company analyst hey guy thanks taking question alzheimers disease agitation program enrolling openlabel extension advance new accord study really imply already got longterm safety data required potential ax filing indication second one messaging accord could pivotal study required case believe accord went protocol amendment obviously concluded early think messaging may pivotal first started turn guess changed say accord would pivotal accord thanksherriot tabuteau chief executive officer thanks thanks question regard openlabel extension study continue enroll openlabel safety extension trial reminder requires trying meet ich guideline patient treated six month patient treated one year well track accomplish goal accord affect also patient completing accord also able go continue dosed comfortable regard meeting necessary number patient relates accord pivotal study also comparing accord nice accord completed accord learning term term confidence around endpoint would necessary study like able design accord prospectively also received feedback fda could registration trial based design think know fact accord designing designed benefit knowledge accord benefit casemyles minter william blair company analyst thanks questionsoperatorour next question come troy langford td cowen please proceed questiontroy langford td cowen analyst hey congrats progress quarter thanks taking question ax confident feel fda would need clinical efficacy perspective approve application sunosi provide additional color powering assumption phase trial mddmark jacobson chief operating officer troy hey take mark know targeting quarter know term content essentially complete know thing finalized really building submission going going take time get robust possible work substantially completeherriot tabuteau chief executive officer relates powering solriamfetol mdd powered study similar similarly way powered study major depressive disorder know quite bit experience auvelity program think powering similar think know general study effect size one would expect drug well laid lot precedent powered study summarize powered detect effect size similar effect size detected auvelity programtroy langford td cowen analyst great thanks coloroperatorsince question turn call back axsomes ceo concluding remarksherriot tabuteau chief executive officer well thank taking time join u today quarterly update first quarter mark strong progress axsome look continue focus commercial pipeline execution throughout balance year goal delivering innovation value patient healthcare professional investor alike thank great rest dayoperatoroperator signoff duration minutescall participantsdarren opland director corporate communicationsherriot tabuteau chief executive officernick pizzie chief financial officerari maizel executive vice president head commercialcharles duncan cantor fitzgerald analystleonid timashev rbc capital market analystash verma ubs analystram selvaraju hc wainwright company analystmarc goodman leerink partner analystdavid amsellem piper sandler analystyatin suneja guggenheim partner analystjason gerberry bank america merrill lynch analystjoon lee truist security analystjoel beatty robert w baird company analystdavid hoang citi analystavantika joshi mizuho security analystvikram purohit morgan stanley analystmatt kaplan ladenburg thalmann company analystmyles minter william blair company analysttroy langford td cowen analystmark jacobson chief operating officer axsm analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends axsome therapeutic motley fool disclosure policy